American Century Companies’s Arcutis Biotherapeutics ARQT Stock Holding History

American Century Companies’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.5M	Buy	1,925,031 +461,803	+32%	+$10.8M	0.02%	856
2026 Q1	$34.5M	Sell	1,463,228 -3,948	-0.3%	-$101K	0.02%	927
2025 Q4	$42.6M	Sell	1,467,176 -195,294	-12%	-$5M	0.02%	798
2025 Q3	$31.3M	Sell	1,662,470 -61,837	-4%	-$975K	0.02%	920
2025 Q2	$24.2M	Buy	1,724,307 +71,815	+4%	+$1.01M	0.01%	1000
2025 Q1	$25.8M	Buy	1,652,492 +21,266	+1%	+$300K	0.02%	917
2024 Q4	$22.7M	Buy	1,631,226 +166,915	+11%	+$1.83M	0.01%	981
2024 Q3	$13.6M	Buy	1,464,311 +232,611	+19%	+$2.3M	0.01%	1183
2024 Q2	$11.5M	Buy	1,231,700 +190,754	+18%	+$1.73M	0.01%	1190
2024 Q1	$10.3M	Buy	1,040,946 +129,143	+14%	+$964K	0.01%	1193
2023 Q4	$2.95M	Buy	911,803 +401,709	+79%	+$1.09M	﹤0.01%	1598
2023 Q3	$2.71M	Buy	510,094 +215	+0%	+$1.83K	﹤0.01%	1574
2023 Q2	$4.86M	Buy	509,879 +1,860	+0.4%	+$20.6K	﹤0.01%	1323
2023 Q1	$5.58M	Sell	508,019 -72,870	-13%	-$1.05M	﹤0.01%	1227
2022 Q4	$8.6M	Sell	580,889 -2,047	-0.4%	-$35.8K	0.01%	1024
2022 Q3	$11.1M	Buy	582,936 +18,292	+3%	+$414K	0.01%	851
2022 Q2	$12M	Buy	564,644 +40,085	+8%	+$822K	0.01%	846
2022 Q1	$10.1M	Buy	524,559 +37,488	+8%	+$634K	0.01%	914
2021 Q4	$10.1M	Buy	487,071 +110,997	+30%	+$2.21M	0.01%	881
2021 Q3	$8.98M	Sell	376,074 -546	-0.1%	-$12.5K	0.01%	874
2021 Q2	$10.3M	Buy	376,620 +824	+0.2%	+$23.2K	0.01%	805
2021 Q1	$10.9M	Buy	375,796 +87,496	+30%	+$2.73M	0.01%	761
2020 Q4	$8.11M	Buy	+288,300	New	+$7.06M	0.01%	799

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

American Century Companies's ARQT Position: Q2 2026 in Review

American Century Companies increased its Arcutis Biotherapeutics (ARQT) stake by 32% in Q2 2026, buying an estimated $10.8M and bringing the position to 1,925,031 shares worth $50.5M. The position accounts for 0.02% of the portfolio, ranked #856.

American Century Companies first reported a position in ARQT in Q4 2020 and has held it in 23 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

American Century Companies held 1,925,031 shares of Arcutis Biotherapeutics worth $50.5M as of Q2 2026.
American Century Companies bought 461,803 Arcutis Biotherapeutics shares in Q2 2026, an estimated $10.8M.
Arcutis Biotherapeutics made up 0.02% of American Century Companies's portfolio in Q2 2026, its #856 holding.
American Century Companies first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 23 quarters since.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.